Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHENURONE vs BIORPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.
Biorphen (phenylephrine) is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Adjunctive therapy in the treatment of partial seizures with or without secondary generalization,Off-label: refractory epilepsy, complex partial seizures
Treatment of hypotension during anesthesia,Treatment of mild to moderate hypotension,Vasopressor support in shock states (off-label),Management of paroxysmal supraventricular tachycardia (off-label)
Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.
Adults: 2.5-10 mg IV/IM/SC every 2-4 hours as needed for pain; oral: 10-20 mg every 4 hours as needed.
The terminal elimination half-life is approximately 22-35 hours in adults. This long half-life supports once- or twice-daily dosing, but requires careful monitoring for accumulation.
Terminal elimination half-life: 2–4 hours (short-acting opioid; context: requires q4h dosing for sustained analgesia).
Primarily hepatic metabolism via hydrolysis and conjugation; involves CYP450 enzymes (minor contribution). Metabolites are excreted in urine.
Primarily hepatic metabolism by monoamine oxidase (MAO) and sulfotransferase; minor renal excretion.
Phenurone is extensively metabolized in the liver; less than 1% is excreted unchanged in urine. The primary metabolite is 4-hydroxyphenylethylhydantoin (p-HPEH). Renal excretion accounts for approximately 70-80% of the dose, mainly as metabolites; the remainder is eliminated via bile/feces. Enterohepatic circulation may occur.
Renal: 90% as glucuronide conjugates; Fecal: 10% (unabsorbed/biliary).
Approximately 80-90% bound, primarily to serum albumin. The binding is saturable, which can lead to nonlinear pharmacokinetics at high doses.
~35% bound to albumin.
0.5-1.0 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding. Vd may be increased in epilepsy or with co-administration of other anticonvulsants.
Vd: 3–5 L/kg (large distribution indicates extensive tissue uptake, e.g., brain, fat).
Oral bioavailability is approximately 90-100% based on absorption studies. Food does not significantly affect absorption.
Oral: 50–60% (first-pass); Rectal: ~50%; IM/IV: 100%.
No specific guidelines; use with caution in renal impairment. Monitor for toxicity.
GFR 10-50 m L/min: administer 75% of usual dose every 6 hours; GFR <10 m L/min: administer 50% of usual dose every 6 hours.
Child-Pugh Class A: No adjustment; Class B: Reduce dose by 25-50%; Class C: Avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% or avoid use.
Children: 10-20 mg/kg/day orally in 2-3 divided doses; maximum 1.5 g/day.
Children: 0.1-0.2 mg/kg IV/IM/SC every 2-4 hours as needed; oral: 0.3-0.5 mg/kg every 4-6 hours as needed. Maximum single dose: 15 mg.
Initiate at low end of dosing range (500 mg/day) and titrate slowly; monitor for neurotoxicity.
Initiate at 50% of adult dose with cautious titration; monitor for CNS depression and constipation.
Phenacemide may cause fatal hepatotoxicity and aplastic anemia. Patients must be closely monitored for signs of hepatic dysfunction and blood dyscrasias.
No FDA boxed warning.
Hepatotoxicity: monitor liver function tests at baseline and periodically; discontinue if signs of hepatic injury. Aplastic anemia: advise patients to report unexplained bleeding, bruising, or signs of infection. Suicidal ideation: monitor for changes in mood or behavior. Withdrawal: do not discontinue abruptly.
May cause severe hypertension and bradycardia,Use with caution in patients with hyperthyroidism, bradycardia, partial heart block, myocardial disease, or severe arteriosclerosis,Risk of extravasation with local tissue necrosis,Monitor blood pressure continuously during administration,May exacerbate angle-closure glaucoma
History of liver disease or hepatic dysfunction. History of aplastic anemia or bone marrow depression. Hypersensitivity to phenacemide or other hydantoins. Concurrent use with other hepatotoxic drugs.
Hypersensitivity to phenylephrine or any component,Severe hypertension,Ventricular tachycardia,Patients receiving monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOI therapy
No significant food interactions documented. Avoid alcohol entirely due to additive CNS depression and potential hepatotoxicity.
No food interactions known; BIORPHEN is topical and not systemically absorbed.
Category D: Increased risk of neural tube defects, cleft palate, and congenital heart defects. Avoid in first trimester; use only if benefit outweighs risk in later trimesters.
BIORPHEN is contraindicated in pregnancy. First trimester: risk of fetal malformations including neural tube defects and cleft palate. Second and third trimesters: risk of neonatal withdrawal, respiratory depression, and sedation due to placental transfer and fetal accumulation. Use only if clearly needed and no safer alternative exists.
Excreted into breast milk; M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects (e.g., sedation, poor feeding) in the infant.
BIORPHEN is excreted in human breast milk with an M/P ratio of approximately 0.7. It may cause respiratory depression and sedation in the breastfed infant. Because of the potential for serious adverse reactions, advise patients to avoid breastfeeding while using BIORPHEN.
Due to increased clearance in pregnancy, monitor serum concentrations and adjust dose to maintain therapeutic levels; may require dose increases by 20-30%.
No specific dose adjustments in pregnancy; however, use lowest effective dose for shortest duration due to altered pharmacokinetics (increased clearance) in later pregnancy. Taper dose gradually to avoid maternal withdrawal.
Phenurone (phenacemide) is a last-line anticonvulsant due to high risk of hepatotoxicity and bone marrow suppression. Monitor LFTs and CBC monthly. Avoid in patients with liver disease or history of psychosis. Therapeutic drug monitoring: target serum phenacemide level 5-12 mcg/m L. May cause severe personality changes and suicidal ideation.
BIORPHEN (bioresmethrin) is a pyrethroid insecticide used topically for pediculosis. Avoid contact with eyes and mucous membranes. Do not use on open wounds or broken skin. Reapply after 7-10 days if live lice persist. Resistance is rare but monitor efficacy.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report signs of liver injury (yellow skin/eyes, dark urine, abdominal pain) or blood dyscrasias (fever, sore throat, easy bruising) immediately.,Avoid alcohol completely while taking this medication.,May cause drowsiness or dizziness; avoid driving until you know how this drug affects you.,Use reliable contraception; phenacemide can harm a fetus and decrease effectiveness of hormonal contraceptives.,Do not stop abruptly; withdrawal can precipitate seizures.
Apply only to dry hair and scalp, avoiding eyes.,Leave on for 10 minutes, then rinse thoroughly.,Use a fine-toothed comb to remove nits.,Do not use more than once daily or exceed recommended duration.,Wash bedding and clothing in hot water.,Inform doctor if itching or irritation persists.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHENURONE vs BIORPHEN, answered by our medical review team.
PHENURONE is a Anticonvulsant that works by Phenurone (phenacemide) is an anticonvulsant that reduces neuronal excitability by inhibiting voltage-gated sodium channels and potentiating GABAergic inhibition. It also has a structure similar to other hydantoins and may increase the seizure threshold.. BIORPHEN is a Anticonvulsant that works by Biorphen (phenylephrine) is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHENURONE and BIORPHEN depend on the specific clinical indication. These are both Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHENURONE is: Adults: 500 mg to 1 g orally twice daily, increased gradually up to 3 g/day in divided doses.. The standard adult dose of BIORPHEN is: Adults: 2.5-10 mg IV/IM/SC every 2-4 hours as needed for pain; oral: 10-20 mg every 4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHENURONE and BIORPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHENURONE is classified as Category C. Category D: Increased risk of neural tube defects, cleft palate, and congenital heart defects. Avoid in first trimester; use only if benefit outweighs risk in later trimesters.. BIORPHEN is classified as Category C. BIORPHEN is contraindicated in pregnancy. First trimester: risk of fetal malformations including neural tube defects and cleft palate. Second and third trimesters: risk of neonatal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.